


Provided for non-commercial research and education use.  
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>

# Leptin-Mediated Neuroendocrine Alterations in Anorexia Nervosa: Somatic and Behavioral Implications

Timo D. Müller<sup>a</sup>, Manuel Föcker, MD<sup>a</sup>, Kristian Holtkamp, MD<sup>b</sup>, Beate Herpertz-Dahlmann, MD<sup>b</sup>, Johannes Hebebrand, MD<sup>a,\*</sup>

## KEYWORDS

- Hyperactivity • Semi-starvation • Osteoporosis • Amenorrhea
- Hypoleptinemia • Hyperleptinemia • Weight loss

In 1953, Kennedy<sup>1</sup> postulated that circulating signals from the periphery that change in relation to body fat stores inform the brain about changes in body fat mass and that the brain in response to these signals adjusts food intake and energy balance to achieve body weight maintenance. The first peripheral hormone implicated in the regulation of food intake was the pancreatic hormone insulin.<sup>2</sup> Positional cloning of the mouse *obese (ob)* gene in 1994 led to the discovery of leptin, a 16-kDa protein that is mainly secreted by white adipocytes and that, in relation to body fat mass, enters the brain through the bloodstream to activate central neuronal circuits to reduce food intake and to increase energy expenditure.<sup>3</sup>

Leptin is secreted into the bloodstream in a pulsatile manner and shows a diurnal variation in normal and overweight individuals, with an increase of about 50% during the night.<sup>4</sup> In anorectic individuals, however, this diurnal variation of leptin secretion is strikingly reduced.<sup>5,6</sup> Plasma levels of leptin further correlate with the amount of body fat.<sup>7</sup> Individuals with a low body fat mass (eg, patients with anorexia nervosa [AN]) have consistently been reported to show low to undetectable plasma levels of leptin.<sup>8</sup> Additionally, even after correction for body mass index (BMI) or body fat mass, plasma levels of leptin have repeatedly been shown to be higher in females than in males.<sup>7,9,10</sup>

---

This work was supported by grants from the Federal Ministry of Education and Research (NGFN2; 01GS0482, 01GS0483) and (01GV0602 360372), the European Union (FP6 LSHMCT-2003-503041), and the Deutsche Forschungsgemeinschaft (DFG; HE 1446/4-1).

<sup>a</sup> Department of Child and Adolescent Psychiatry and Psychotherapy, University of Duisburg-Essen, Virchowstrasse 174, 45147 Essen, Germany

<sup>b</sup> Department of Child and Adolescent Psychiatry and Psychotherapy, University Clinics, RWTH Aachen, Neuenhofer Weg 21, 52074 Aachen, Germany

\* Corresponding author.

E-mail address: [johannes.hebebrand@uni-duisburg-essen.de](mailto:johannes.hebebrand@uni-duisburg-essen.de) (J. Hebebrand).

Child Adolesc Psychiatric Clin N Am 18 (2008) 117–129

doi:10.1016/j.chc.2008.07.002

1056-4993/08/\$ – see front matter © 2008 Elsevier Inc. All rights reserved.

[childpsych.theclinics.com](http://childpsych.theclinics.com)

A multiple regression analysis with BMI and percent body fat as fixed variables further revealed that testosterone is negatively correlated with plasma levels of leptin in boys, but not in girls, thus indicating that higher androgen concentrations are at least partly responsible for the observed lower leptin concentrations in boys.<sup>10</sup> Plasma levels of leptin, however, decline on food deprivation and become similar in both sexes after a 36-hour fast.<sup>11</sup>

Since its discovery in 1994, a tremendous amount of research has focused on leptin-mediated signaling pathways, revealing that leptin is not only a key hormone implicated in the regulation of energy balance but it is also a pleiotropic hormone involved in various neuroendocrine and behavioral alterations associated with profound changes in energy stores. The observation that obese leptin-deficient *ob/ob* mice show endocrine abnormalities similar to those observed in semi-starved *wild-type* mice, together with the observation that prevention of the starvation-induced fall in leptin by exogenous leptin supplementation substantially blunts the changes in the hypothalamic–pituitary–adrenal (HPA), –gonadal (HPG), and –thyroid (HPT) axes, has led to the hypothesis that leptin is a key hormone mediating the neuroendocrine response to semi-starvation.<sup>12</sup> Indeed, hypoleptinemia induced by profound weight loss turned out to mediate various physiologic and endocrinologic alterations associated with reduced body weight, such as modulation of bone formation,<sup>13–15</sup> inflammation,<sup>16,17</sup> reproduction,<sup>18–21</sup> and the regulation of the HPA<sup>12,22,23</sup> and HPA–thyroidT axis.<sup>24</sup>

As leptin plays an important role in the adaptation of an organism to semi-starvation, AN can be considered as a model disorder to elucidate the relationship between hypoleptinemia induced by profound weight loss and the somatic, behavioral, and neuroendocrine alterations associated with semi-starvation. Moreover, patients with AN share many physiologic, endocrinologic, and behavioral features with healthy subjects who voluntarily or involuntarily lost a substantial amount of body weight, such as osteopenia/osteoporosis, amenorrhea, hyperactivity, hypothermia, bradycardia, reduced basal metabolic rate, and activation of the HPA axis.<sup>8</sup> However, even though AN shares many neuroendocrine and behavioral similarities with healthy subjects undergoing semi-starvation, the diagnostically relevant psychopathological features clearly distinguishing AN from weight reduced healthy subjects are the intense fear of gaining weight and the undue influence of body weight on self-evaluation.

In light of the postulated critical role of leptin in the adaptation of an organism to semi-starvation, the focus of this review is to summarize the pivotal role of leptin in the neuroendocrine response to profound weight loss, with special emphasis on AN. In particular, we focus on the effects of semi-starvation–induced hypoleptinemia on the HPA and HPG axis, bone formation, and the hyperactivity in patients with AN. Additionally, we highlight the consolidated findings obtained in the “activity-based anorexia” rat model, which serves as an animal model for AN.

#### LEPTIN LEVELS IN PATIENTS WITH AN

Hypoleptinemia is a cardinal feature of acute AN, and in most studies mean leptin levels only rarely exceed  $2 \mu\text{g/L}^{-1}$  on referral;<sup>8</sup> the low leptin levels are typically below those of healthy gender- and age-matched controls and reflect the low fat mass. The highest plasma leptin levels in patients with AN were reported by Grinspoon and colleagues<sup>25</sup> with  $5.6 \pm 3.7 \mu\text{g/L}^{-1}$ ; the variation in mean leptin concentration might at least partly be explained by the time point of blood sampling, because weight regain leads to an increase in leptin secretion. This time point varies among the different studies from “at a baseline visit”<sup>26,27</sup> or “within the first days upon referral”<sup>18,19,28–34</sup> to “at the end of a 3-week nutritional stabilization phase” or “after a minimum weight gain of

10%.”<sup>35</sup> Other studies do not specify when during the course of treatment blood was sampled.<sup>8</sup> Leptin levels, however, can only be compared between studies when blood is collected at the same point in time, optimally within the first 1 to 3 days on referral, as leptin levels expeditiously increase on initiation of a refeeding therapy;<sup>20,29,34,36,37</sup> accordingly, leptin levels have increased from those observed on admission after 30 days of refeeding<sup>36</sup> or after a body weight gain of 5%.<sup>37</sup> However, several lines of evidence further indicate that the increase in leptin levels on refeeding is also dependent on the severity of hypoleptinemia; patients with exceedingly low plasma levels of leptin on admission show only slight linear increases in the initial phase of weight regain, which is typically followed by a subsequently more rapid increase.<sup>20,29</sup> Several studies have further shown that hyperleptinemia can ensue from the therapeutically induced weight gain in both female<sup>20,29</sup> and male<sup>19</sup> patients with AN, thus indicating that hyperleptinemia in these patients might contribute to difficulties in long-term weight restoration and body weight maintenance. However, not all studies have been able to confirm this finding,<sup>34</sup> possibly because of different rates of therapeutically induced weight gain or differences in the second time point at which patients' blood was sampled.

In most studies plasma levels of leptin were highly correlated with percent body fat<sup>5,20,25,27,34,38</sup> and, to a lesser extent, with BMI on referral;<sup>5,20,25,27,29</sup> only few studies failed to detect a clear correlation<sup>39,40</sup> including the first study to analyze leptin levels in AN patients using an ELISA.<sup>39</sup>

#### HYPOTHALAMIC–PITUITARY–ADRENAL AXIS

Generally, activation of the HPA axis in response to acute stress conditions is mediated through an increased secretion of hypothalamic corticotropin-releasing hormone (CRH), which is transported through the portal system to the pituitary where CRH stimulates the production of adrenocorticotrophic hormone (ACTH); increased secretion of glucocorticoids from the adrenal gland ensues.<sup>41</sup>

Hypercortisolism has consistently been reported in patients with acute AN.<sup>5,14,31,41–47</sup> This is partly provoked by an increased secretion of CRH in the hypothalamus and partly by an increased half-life of cortisol due to a decreased cortisol metabolism.<sup>5,41</sup> Serum levels of cortisol, however, decline on weight regain<sup>48,49</sup> and become similar to those observed in controls after weight reconstitution.<sup>48</sup>

In accordance with the findings in AN patients, activation of the HPA axis is increased in voluntarily fasted healthy subjects<sup>50–52</sup> as well as in rats<sup>53</sup> and mice<sup>12,22</sup> undergoing semi-starvation; corticosterone levels are increased. In 1996, Ahima and colleagues<sup>12</sup> first postulated that semi-starvation-induced hypoleptinemia mediates the activation of the HPA axis under severe conditions of reduced energy availability. The hypothesis was based on the observation that leptin supplementation blunts hypercorticosteronemia in semi-starved *wild-type* mice<sup>12</sup> and in obese leptin deficient *ob/ob* mice.<sup>22,54</sup> Additionally, the stress-induced increase in hypothalamic CRH release was inhibited by leptin supplementation in a dose-dependent manner.<sup>22</sup>

#### AMENORRHEA AND REPRODUCTIVE FUNCTION

Secondary amenorrhea defined as the absence of at least 3 consecutive menstrual cycles in postmenarchal females represents the fourth edition of Diagnostic and statistical manual of mental disorders diagnostic criterion for AN.<sup>55</sup> However, secondary amenorrhea is not confined to patients with AN; also healthy females with relatively low body fat mass, for example, underweight women,<sup>30</sup> women with anorexia athletica,<sup>38</sup> and elite women athletes<sup>56</sup> show an elevated incidence of amenorrhea and

disturbances in menstrual function. The observation that delayed puberty and menstrual irregularities are frequently observed in relatively thin girls has, long before the discovery of leptin, led to the hypothesis that a critical amount of body weight or body fat mass is required for the onset and maintenance of cyclical ovulation.<sup>57</sup>

In the state of semi-starvation the occurrence of amenorrhea reflects the physiologic neuroendocrine adaptation; adequate energy stores to sustain a pregnancy and to provide adequate nutrition to both the fetus and the mother are not available. Based on the observation that both rodents<sup>58,59</sup> and humans<sup>60,61</sup> with mutations in the leptin receptor gene or with leptin deficiency due to mutations in the leptin gene are amenorrheic and that infertility of obese leptin-deficient *ob/ob* mice can be restored by exogenous leptin supplementation,<sup>58,59</sup> it was postulated that initiation and maintenance of the human menstrual cycle requires endogenous plasma levels of leptin above a specific threshold value; accordingly amenorrhea ensues on attainment of subthreshold leptin levels. We have determined that this threshold value is around 2 µg/L.<sup>30</sup> Accordingly, plasma levels of leptin turned out to be a better predictor of amenorrhea than BMI, fat mass, or percent body fat,<sup>30</sup> thus indicating that the drop in leptin levels mediated by profound weight loss represents the first step of a neuroendocrine cascade that shuts off the HPG axis. Further studies confirmed that a drop in leptin levels below a critical threshold lowers the production of central gonadotropin-releasing hormone (GnRH), leading to decreased levels of the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which in turn entails a curtailment of ovarian estrogen production.<sup>18,30,62,63</sup> Several studies further indicate that cocaine- and amphetamine-regulated transcript (CART) might be an important mediator of leptin's action on GnRH secretion<sup>64,65</sup> and that the drop in leptin levels below a critical threshold suppresses GnRH secretion through an upregulation of CART in the hypothalamus.<sup>8,65</sup>

In patients with AN the increase in leptin levels due to a refeeding therapy leads to increments of FSH and LH secretion when leptin levels exceed 1.2 µg/L (FSH)<sup>20</sup> and 1.85 µg/L (LH),<sup>18</sup> respectively. Accordingly, treatment of amenorrheic women with recombinant leptin increased mean LH levels and LH pulse frequency after 2 weeks and increased maximal follicular diameter, the number of dominant follicles, ovarian volume, and estradiol levels over a period of 3 months;<sup>66</sup> these females did not fulfill criteria for AN at the time of the study. However, in patients with acute AN, increments of leptin levels and subsequently of the gonadotropins are not able to rapidly restore regular menstruation; 85% of adolescents with AN resumed menses within 6 months after restoration of 90% of standard weight.<sup>67</sup> Obviously, it takes time for the reproduction axis to normalize, including the renewed growth of the ovaries.

## BONE FORMATION

A persisting decrease in bone mineral density (BMD) is one of the most profound long-term consequences of prolonged AN,<sup>8,68,69</sup> and the association of BMD deficiency with AN has consistently been shown in both female<sup>68-72</sup> and male patients with AN.<sup>73</sup> The peak physiologic calcium accretion and bone mass accrual is between age 11 and 16 years<sup>74-76</sup> and this time coincides with the highest incidence for the development of AN.<sup>77</sup> Sufficient energy availability is crucial for bone mass development during this period, and prolonged semi-starvation at this age is an important risk factor for the development and persistence of osteopenia and osteoporosis later in life.<sup>8</sup> Indeed, the decrease in BMD is not immediately restored on weight regain<sup>69,70,78-80</sup> and 1 study even reported persisting BMD deficiency more than 10 years after the diagnosis of AN.<sup>78</sup> Accordingly, osteopenia and osteoporosis have consistently been

described in 50% to 92% and 13% to 38% of patients with AN, respectively.<sup>25,81</sup> In light of these long-term complications, it is not surprising that anorectic patients show a 7-fold increased incidence of spontaneous fractures<sup>82</sup> and 1 study even reported a 57% cumulative incidence of fractures at the hip, radius, and spine 40 years after the diagnosis of AN.<sup>83</sup>

Semi-starvation-induced hypercortisolism is implicated in the development of BMD deficiency, and thus osteopenia and osteoporosis, as high serum levels of cortisol inhibit bone formation, increase bone resorption, impair calcium absorption from the gut, and affect the secretion of several hormones implicated in bone metabolism.<sup>13,14,84,85</sup> Leptin, however, is indirectly involved in the frequently observed BMD deficiency in AN, because semi-starvation-induced hypoleptinemia entails hypercortisolism due to activation of the HPA axis. Several lines of evidence further indicate that leptin also directly influences bone metabolism; leptin is known to stimulate the expression and secretion of central CART,<sup>86</sup> which inhibits bone loss through inhibition of bone resorption.<sup>87</sup> Thus, semi-starvation-induced hypoleptinemia in combination with an autonomic dysfunction might at least partly explain the consistently observed impairment of bone metabolism in patients with AN.<sup>8</sup>

#### HYPERACTIVITY IN PATIENTS WITH AN AND SEMI-STARVED RATS

Elevated levels of physical activity are commonly observed in patients with AN<sup>8,28,33,88–93</sup> and some investigators view this phenomenon as a core clinical symptom of AN.<sup>8,88,91,94</sup> In light of the lack of a consistent operational definition of “hyperactivity,” excessive exercise is described in 31% to 80% of patients with AN.<sup>91</sup> In some studies, patients with AN were reported to have an addictive, obsessive-compulsive drive to exercise.<sup>90,91,95</sup> The hypothesis that physiologic mechanisms due to semi-starvation underlie this phenomenon was supported by the observation that rats increase their running wheel activity up to 300% to 500% within a few days, when food is either supplied for only a limited period per day (eg, 1–2 h/d)<sup>96–99</sup> or when food is restricted to 60% of the ad libitum food intake.<sup>32</sup> In the most extreme cases, in which food was only supplied for 1 h/d, rats even ran themselves to death within approximately 21 days.<sup>100</sup> This phenomenon called “activity based anorexia” (ABA)<sup>101</sup> or “semi-starvation-induced hyperactivity” (SIH) is considered as an animal model of AN,<sup>8,32,91,98</sup> which shows several symptoms of AN, such as weight loss, low adiposity, hypothermia, low leptin levels, high levels of physical activity, and, in females amenorrhea.<sup>91</sup>

In 2000, Exner and colleagues<sup>32</sup> first postulated that semi-starvation-induced hypoleptinemia triggers SIH. The hypothesis was confirmed experimentally by way of subcutaneous implantation of mini-pumps containing leptin or vehicle in rats undergoing semi-starvation; vehicle treated rats increased their activity up to 300% within 7 days, whereas the activity of the leptin treated rats remained at baseline.<sup>32</sup> A second experiment showed that leptin normalized activity levels even after SIH had set in.<sup>32</sup> The suppression of SIH by exogenous application of leptin was subsequently confirmed by an independent group.<sup>98</sup>

The SIH triggered by hypoleptinemia in rats suggests that the same mechanism might underlie the hyperactivity in patients with AN. Indeed, Exner and colleagues<sup>32</sup> reported the highest levels of restlessness (assessed by self-ratings) in patients with AN when leptin levels and body weight were at their lowest. Additionally, activity levels decreased when leptin levels and body mass increased owing to inpatient treatment.<sup>32</sup> Consistently, serum leptin levels were negatively correlated with motor restlessness (assessed by expert ratings using visual analog scales) in 61 females with

AN.<sup>33</sup> The result was independently confirmed in 27 adolescents with AN, in whom motor restlessness was assessed by expert ratings using the Structured Inventory for Anorectic and Bulimic Syndromes (SIAB).<sup>33</sup> To corroborate these findings, various qualities of physical activity (excessive exercise, motor and inner restlessness) were assessed by accelerometry and self- and expert ratings in an independent sample of 26 inpatients with AN; leptin levels were significantly associated with all qualities of activity and restlessness.<sup>28</sup>


Semi-starvation-induced hyperactivity is seemingly not confined to patients with AN. Thus, survivors of captivity after World War II reported an increase in activity, productivity, and creativity in the initial phase of reduced food availability.<sup>91,102,103</sup> Additionally, voluntary periods of severe food restriction (“fasting cures”) are practiced frequently in the European population as part of a traditional self-care health-promoting activity, and these voluntary fasting cures have been shown to be associated with mood enhancement, leptin depletion, and activation of the HPA axis.<sup>50,51</sup>

The increase in activity levels in times of reduced energy availability has been interpreted as increased foraging behavior. Thus, in evolutionary terms, starvation-induced increase in activity levels might be a phylogenetically old pathway to increase the odds for survival.<sup>91</sup> The decrease in activity due to application of leptin as a satiety signal supports this hypothesis.

The molecular mechanisms underlying the induction of SIH by hypoleptinemia remain unclear. Several leptin-mediated first- and second-order systems in the brain and the periphery might be associated with the effect of leptin on SIH. These could act in concert; alternatively, a single system underlies SIH. The hypothalamic melanocortinergic (MC) system<sup>86</sup> might be involved in the leptin-mediated effect on SIH, because MC receptor expression is increased in the ventromedial hypothalamus of SIH rats, suggesting that a hyperactive MC system underlies the SIH phenotype.<sup>104</sup> However, central infusion of alpha-melanocyte-stimulating hormone<sup>105</sup> or agouti-related protein<sup>99</sup> had no effect on total daily running activity. Other possible pathways downstream of the leptin receptor that might be implicated in SIH are the serotonergic/dopaminergic system or the HPA axis. The increase in glucocorticoids mediated by semi-starvation-induced activation of the HPA axis might play an important role in the development of SIH, because SIH was completely suppressed in adrenalectomized rats and restored after corticosterone treatment.<sup>106,107</sup> Additionally, application of corticosterone increases locomotor activity in ad libitum-fed rats<sup>108</sup> and mice.<sup>109</sup> In accordance with the animal models, urinary free cortisol has recently been shown to correlate with activity levels (measured by accelerometry) in 36 women with acute AN.<sup>110</sup>

## NEURONAL FUNCTIONS

Recently, several studies have demonstrated that the actions of leptin are not restricted to the hypothalamus and the hypothalamus–pituitary axis. Instead, many other brain areas including brain stem, cerebellum, amygdala, substantia nigra, and especially the hippocampus are highly enriched with leptin receptors. New findings indicate an enhancement of *N*-methyl-D-aspartic acid receptor function and hippocampal long-term potentiation by leptin and thus underline the importance of this hormone in hippocampal learning and memory function.<sup>111</sup> Accordingly, memory impairments are observed in leptin-insensitive rodents, whereas leptin administration improves memory processes. Interestingly, severely underweight anorectic patients also display memory deficits, especially concerning working memory, which often alleviate with weight gain.<sup>112</sup>



**Fig. 1.** Semi-starvation-induced alterations of the hypothalamus–pituitary–adrenal (HPA) and –gonadal (HPG) axis in patients with anorexia nervosa. ACTH, adrenocorticotropic hormone; GnRH, gonadotropin-releasing hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; BMD, bone mineral density; ↑, increased; ↓, decreased; dashed line, indirect influence; continuous line, direct influence.

## SUMMARY

The crucial role of leptin in the neuroendocrine alterations associated with AN is indisputable (**Fig. 1**). Plasma levels of leptin are strikingly reduced during the acute phase of the disorder and increase on weight regain. Whereas hypercortisolism rapidly normalizes on weight restoration, disturbances of ovarian function and decreased BMD can persist for several months up to years after body weight has been restored to normal values. The degree of hypoleptinemia in the acute phase of AN can be considered as an indicator of the severity of the disorder; the lower the leptin level, the more semi-starvation has progressed, and the less adipose tissue exerts its pleiotropic function on other tissues. Accordingly, secretion of gonadotropins (FSH, LH) decreases when leptin levels drop below specific thresholds, thus entailing the development of amenorrhea. Hypoleptinemia-induced hyperactivity reminds us of the difficulty to distinguish between primary and secondary (semi-starvation induced) psychopathological symptoms in AN.

In light of the pivotal role of leptin in mediating the neuroendocrine alterations associated with semi-starvation, the determination of leptin levels should become part of the routine clinical evaluation at referral.<sup>8</sup> It was previously also discussed to include hypoleptinemia as a diagnostic criterion of AN.<sup>94</sup> A prerequisite of that recommendation would be the definition of both the normal reference range and the range of leptin levels observed in patients with AN. As leptin levels potentially differ from those on admission after initiation of weight restoration, the time point of blood sampling needs to be considered when comparing different studies. Measurement of leptin levels may potentially help to detect AN early on during childhood and to assess the severity of the disorder.

## REFERENCES

1. Kennedy GC. The role of depot fat in the hypothalamic control of food intake in the rat. *Proc R Soc Lond B Biol Sci* 1953;140:578–96.
2. Woods SC, Lotter EC, McKay LD, et al. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. *Nature* 1979;282:503–5.
3. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. *Nature* 1994;372:425–32.
4. Licinio J, Mantzoros C, Negrao AB, et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. *Nat Med* 1997;3:575–9.
5. Stoving RK, Vinten J, Handberg A, et al. Diurnal variation of the serum leptin concentration in patients with anorexia nervosa. *Clin Endocrinol (Oxf)* 1998;48:761–8.
6. Balligand JL, Brichard SM, Brichard V, et al. Hypoleptinemia in patients with anorexia nervosa: loss of circadian rhythm and unresponsiveness to short-term refeeding. *Eur J Endocrinol* 1998;138:415–20.
7. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. *Nat Med* 1995;1:1155–61.
8. Hebebrand J, Müller TD, Holtkamp K, et al. The role of leptin in anorexia nervosa: clinical implications. *Mol Psychiatry* 2007;12:23–35.
9. Havel PJ, Kasim-Karakas S, Dubuc GR, et al. Gender differences in plasma leptin concentrations. *Nat Med* 1996;2:949–50.
10. Wabitsch M, Blum WF, Muche R, et al. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. *J Clin Invest* 1997;100:808–13.
11. Maccario M, Aimaretti G, Corneli G, et al. Short-term fasting abolishes the sex-related difference in GH and leptin secretion in humans. *Am J Physiol Endocrinol Metab* 2000;279:E411–6.
12. Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. *Nature* 1996;382:250–2.
13. Heer M, Mika C, Grzella I, et al. Changes in bone turnover in patients with anorexia nervosa during eleven weeks of inpatient dietary treatment. *Clin Chem* 2002;48:754–60.
14. Heer M, Mika C, Grzella I, et al. Bone turnover during inpatient nutritional therapy and outpatient follow-up in patients with anorexia nervosa compared with that in healthy control subjects. *Am J Clin Nutr* 2004;80:774–81.
15. Eleftheriou F. Neuronal signaling and the regulation of bone remodeling. *Cell Mol Life Sci* 2005;62:2339–49.
16. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. *FASEB J* 1998;12:57–65.
17. Gualillo O, Eiras S, Lago F, et al. Elevated serum leptin concentrations induced by experimental acute inflammation. *Life Sci* 2000;67:2433–41.
18. Ballauff A, Ziegler A, Emons G, et al. Serum leptin and gonadotropin levels in patients with anorexia nervosa during weight gain. *Mol Psychiatry* 1999;4:71–5.
19. Wabitsch M, Ballauff A, Holl R, et al. Serum leptin, gonadotropin, and testosterone concentrations in male patients with anorexia nervosa during weight gain. *J Clin Endocrinol Metab* 2001;86:2982–8.
20. Holtkamp K, Mika C, Grzella I, et al. Reproductive function during weight gain in anorexia nervosa. Leptin represents a metabolic gate to gonadotropin secretion. *J Neural Transm* 2003;110:427–35.

21. Bluher S, Mantzoros CS. Leptin in reproduction. *Curr Opin Endocrinol Diabetes Obes* 2007;14:458–64.
22. Heiman ML, Ahima RS, Craft LS, et al. Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress. *Endocrinology* 1997;138:3859–63.
23. Malendowicz LK, Rucinski M, Belloni AS, et al. Leptin and the regulation of the hypothalamic-pituitary-adrenal axis. *Int Rev Cytol* 2007;263:63–102.
24. Martin NM, Smith KL, Bloom SR, et al. Interactions between the melanocortin system and the hypothalamo-pituitary-thyroid axis. *Peptides* 2006;27:333–9.
25. Grinspoon S, Gulick T, Askari H, et al. Serum leptin levels in women with anorexia nervosa. *J Clin Endocrinol Metab* 1996;81:3861–3.
26. Misra M, Soyka LA, Miller KK, et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. *J Clin Endocrinol Metab* 2003;88:3816–22.
27. Misra M, Miller KK, Almazan C, et al. Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity. *J Clin Endocrinol Metab* 2004;89:3486–95.
28. Holtkamp K, Herpertz-Dahlmann B, Hebebrand K, et al. Physical activity and restlessness correlate with leptin levels in patients with adolescent anorexia nervosa. *Biol Psychiatry* 2006;60:311–3.
29. Hebebrand J, Blum WF, Barth N, et al. Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration. *Mol Psychiatry* 1997;2:330–4.
30. Kopp W, Blum WF, von Prittwitz S, et al. Low leptin levels predict amenorrhea in underweight and eating disordered females. *Mol Psychiatry* 1997;2:335–40.
31. Eckert ED, Pomeroy C, Raymond N, et al. Leptin in anorexia nervosa. *J Clin Endocrinol Metab* 1998;83:791–5.
32. Exner C, Hebebrand J, Remschmidt H, et al. Leptin suppresses semi-starvation induced hyperactivity in rats: implications for anorexia nervosa. *Mol Psychiatry* 2000;5:476–81.
33. Holtkamp K, Herpertz-Dahlmann B, Mika C, et al. Elevated physical activity and low leptin levels co-occur in patients with anorexia nervosa. *J Clin Endocrinol Metab* 2003;88:5169–74.
34. Haas V, Onur S, Paul T, et al. Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery. *Am J Clin Nutr* 2005;81:889–96.
35. Tolle V, Kadem M, Bluett-Pajot MT, et al. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. *J Clin Endocrinol Metab* 2003;88:109–16.
36. Haluzik M, Papezova M, Nedvidkova J, et al. Serum leptin levels in patients with anorexia nervosa before and after partial refeeding, relationships to serum lipids and biochemical nutritional parameters. *Physiol Res* 1999;48:197–202.
37. Vaisman N, Hahn T, Karov Y, et al. Changes in cytokine production and impaired hematopoiesis in patients with anorexia nervosa: the effect of refeeding. *Cytokine* 2004;26:255–61.
38. Matejek N, Weimann E, Witzel C, et al. Hypoleptinaemia in patients with anorexia nervosa and in elite gymnasts with anorexia athletica. *Int J Sports Med* 1999;20:451–6.
39. Hebebrand J, van der Heyden J, Devos R, et al. Plasma concentrations of obese protein in anorexia nervosa. *Lancet* 1995;346(8990):1624–5.
40. Mantzoros C, Flier JS, Lesem MD, et al. Cerebrospinal fluid leptin in anorexia nervosa: correlation with nutritional status and potential role in resistance to weight gain. *J Clin Endocrinol Metab* 1997;82:1845–51.

41. Licinio J, Wong ML, Gold PW. The hypothalamic-pituitary-adrenal axis in anorexia nervosa. *Psychiatry Res* 1996;62:75–83.
42. Kennedy SH, Brown GM, McVey G, et al. Pineal and adrenal function before and after refeeding in anorexia nervosa. *Biol Psychiatry* 1991;30:216–24.
43. Monteleone P, Martiadis V, Colurcio B, et al. Leptin secretion is related to chronicity and severity of the illness in bulimia nervosa. *Psychosom Med* 2002;64:874–9.
44. Weinbrenner T, Zittermann A, Gouni-Berthold I, et al. Body mass index and disease duration are predictors of disturbed bone turnover in anorexia nervosa. A case-control study. *Eur J Clin Nutr* 2003;57:1262–7.
45. Weinbrenner T, Zuger M, Jacoby GE, et al. Lipoprotein metabolism in patients with anorexia nervosa: a case-control study investigating the mechanisms leading to hypercholesterolaemia. *Br J Nutr* 2004;91:959–69.
46. Misra M, Miller KK, Bjornson J, et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. *J Clin Endocrinol Metab* 2003;88:5615–23.
47. Misra M, Miller KK, Cord J, et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. *J Clin Endocrinol Metab* 2007;92:2046–52.
48. Gold PW, Gwirtsman H, Avgerinos PC, et al. Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. *N Engl J Med* 1986;314:1335–42.
49. Gwirtsman HE, Kaye WH, George DT, et al. Central and peripheral ACTH and cortisol levels in anorexia nervosa and bulimia. *Arch Gen Psychiatry* 1989;46:61–9.
50. Michalsen A, Kuhlmann MK, Ludtke R, et al. Prolonged fasting in patients with chronic pain syndromes leads to late mood-enhancement not related to weight loss and fasting-induced leptin depletion. *Nutr Neurosci* 2006;9:195–200.
51. Michalsen A, Schneider S, Rodenbeck A, et al. The short-term effects of fasting on the neuroendocrine system in patients with chronic pain syndromes. *Nutr Neurosci* 2003;6:11–8.
52. Fichter MM, Pirke KM. Effect of experimental and pathological weight loss upon the hypothalamo-pituitary-adrenal axis. *Psychoneuroendocrinology* 1986;11:295–305.
53. Djordjevic J, Cvijic G, Davidovic V. Different activation of ACTH and corticosterone release in response to various stressors in rats. *Physiol Res* 2003;52:67–72.
54. Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. *Nature* 1995;377:530–2.
55. American Psychiatric Association. In: Diagnostic and statistical manual of mental disorders DSM-IV. 4th edition. (text revision). Washington, DC: American Psychiatric Publishing; 2000RH, LD, MD, et al. 2007;56:569–79.
56. De Souza MJ, Metzger DA. Reproductive dysfunction in amenorrheic athletes and anorexic patients: a review. *Med Sci Sports Exerc* 1991;23:995–1007.
57. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. *Science* 1974;185:949–51.
58. Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. *Nat Genet* 1996;12:318–20.
59. Mounzih K, Lu R, Chehab FF. Leptin treatment rescues the sterility of genetically obese ob/ob males. *Endocrinology* 1997;138:1190–3.

60. Strobel A, Issad T, Camoin L, et al. A leptin missense mutation associated with hypogonadism and morbid obesity. *Nat Genet* 1998;18:213–5.
61. Clement K, Vaisse C, Lahlou N, et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. *Nature* 1998;392:398–401.
62. Audi L, Mantzoros CS, Vidal-Puig A, et al. Leptin in relation to resumption of menses in women with anorexia nervosa. *Mol Psychiatry* 1998;3:544–7.
63. Chan JL, Mantzoros CS. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. *Lancet* 2005;366:74–85.
64. Parent AS, Lebrethon MC, Gerard A, et al. Leptin effects on pulsatile gonadotropin releasing hormone secretion from the adult rat hypothalamus and interaction with cocaine and amphetamine regulated transcript peptide and neuropeptide Y. *Regul Pept* 2000;92:17–24.
65. Chan JL, Mantzoros CS. Leptin and the hypothalamic-pituitary regulation of the gonadotropin-gonadal axis. *Pituitary* 2001;4:87–92.
66. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. *N Engl J Med* 2004;351:987–97.
67. Golden NH, Jacobson MS, Schebendach J, et al. Resumption of menses in anorexia nervosa. *Arch Pediatr Adolesc Med* 1997;151:16–21.
68. Bachrach LK, Guido D, Katzman D, et al. Decreased bone density in adolescent girls with anorexia nervosa. *Pediatrics* 1990;86:440–7.
69. Soyka LA, Misra M, Frenchman A, et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. *J Clin Endocrinol Metab* 2002;87:4177–85.
70. Bachrach LK, Katzman DK, Litt IF, et al. Recovery from osteopenia in adolescent girls with anorexia nervosa. *J Clin Endocrinol Metab* 1991;72:602–6.
71. Misra M, Miller KK, Almazan C, et al. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. *J Clin Endocrinol Metab* 2004;89:4972–80.
72. Soyka LA, Grinspoon S, Levitsky LL, et al. The effects of anorexia nervosa on bone metabolism in female adolescents. *J Clin Endocrinol Metab* 1999;84:4489–96.
73. Castro J, Toro J, Lazaro L, et al. Bone mineral density in male adolescents with anorexia nervosa. *J Am Acad Child Adolesc Psychiatry* 2002;41:613–8.
74. Bonjour JP, Theintz G, Buchs B, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. *J Clin Endocrinol Metab* 1991;73:555–63.
75. Theintz G, Buchs B, Rizzoli R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. *J Clin Endocrinol Metab* 1992;75:1060–5.
76. Bailey DA, Martin AD, McKay HA, et al. Calcium accretion in girls and boys during puberty: a longitudinal analysis. *J Bone Miner Res* 2000;15:2245–50.
77. Katzman DK. Medical complications in adolescents with anorexia nervosa: a review of the literature. *Int J Eat Disord* 2005;37(Suppl):S52–9 [discussion: S87–9].
78. Brooks ER, Ogden BW, Cavalier DS. Compromised bone density 11.4 years after diagnosis of anorexia nervosa. *J Womens Health* 1998;7:567–74.
79. Golden NH. Osteopenia and osteoporosis in anorexia nervosa. *Adolesc Med* 2003;14:97–108.

80. Mika C, Holtkamp K, Heer M, et al. A 2-year prospective study of bone metabolism and bone mineral density in adolescents with anorexia nervosa. *J Neural Transm* 2007;114:1611–8.
81. Misra M, Klibanski A. Anorexia nervosa and osteoporosis. *Rev Endocr Metab Disord* 2006;7:91–9.
82. Rigotti NA, Neer RM, Skates SJ, et al. The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. *JAMA* 1991;265:1133–8.
83. Lucas AR, Beard CM, O'Fallon WM, et al. 50-year trends in the incidence of anorexia nervosa in Rochester, Minn.: a population-based study. *Am J Psychiatry* 1991;148:917–22.
84. Misra M, Prabhakaran R, Miller KK, et al. Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. *J Clin Endocrinol Metab* 2008;93:1292–7.
85. Chiodini I, Torlontano M, Carnevale V, et al. Skeletal involvement in adult patients with endogenous hypercortisolism. *J Endocrinol Invest* 2008;31:267–76.
86. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. *Nature* 2000;404:661–71.
87. Eleftheriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. *Nature* 2005;434:514–20.
88. Casper RC. Behavioral activation and lack of concern, core symptoms of anorexia nervosa? *Int J Eat Disord* 1998;24:381–93.
89. Casper RC. The 'drive for activity' and "restlessness" in anorexia nervosa: potential pathways. *J Affect Disord* 2006;92:99–107.
90. Holtkamp K, Hebebrand J, Herpertz-Dahlmann B. The contribution of anxiety and food restriction on physical activity levels in acute anorexia nervosa. *Int J Eat Disord* 2004;36:163–71.
91. Hebebrand J, Exner C, Hebebrand K, et al. Hyperactivity in patients with anorexia nervosa and in semistarved rats: evidence for a pivotal role of hypoleptinemia. *Physiol Behav* 2003;79:25–37.
92. van Elburg AA, Hoek HW, Kas MJ, et al. Nurse evaluation of hyperactivity in anorexia nervosa: a comparative study. *Eur Eat Disord Rev* 2007;15:425–9.
93. van Elburg AA, Kas MJ, Hillebrand JJ, et al. The impact of hyperactivity and leptin on recovery from anorexia nervosa. *J Neural Transm* 2007;114:1233–7.
94. Hebebrand J, Casper R, Treasure J, et al. The need to revise the diagnostic criteria for anorexia nervosa. *J Neural Transm* 2004;111:827–40.
95. Davis C, Katzman DK, Kirsh C. Compulsive physical activity in adolescents with anorexia nervosa: a psychobehavioral spiral of pathology. *J Nerv Ment Dis* 1999;187:336–42.
96. Dwyer DM, Boakes RA. Activity-based anorexia in rats as failure to adapt to a feeding schedule. *Behav Neurosci* 1997;111:195–205.
97. Morse AD, Russell JC, Hunt TW, et al. Diurnal variation of intensive running in food-deprived rats. *Can J Physiol Pharmacol* 1995;73:1519–23.
98. Hillebrand JJ, Koeners MP, de Rijke CE, et al. Leptin treatment in activity-based anorexia. *Biol Psychiatry* 2005;58:165–71.
99. Hillebrand JJ, Kas MJ, Scheurink AJ, et al. AgRP(83-132) and SHU9119 differently affect activity-based anorexia. *Eur Neuropsychopharmacol* 2006;16:403–12.
100. Hall JF, Hanford PV. Activity as a function of a restricted feeding schedule. *J Comp Physiol Psychol* 1954;47:362–3.

101. Epling WF, Pierce WD, Stefan L. A theory of activity-based anorexia. *Int J Eat Disord* 1981;3:27–47.
102. Schilling F. Selbstbeobachtungen im Hungerzustand. *Beiträge aus der Allgemeinen Medizin* 1948;6:41–67.
103. Seemann W. Über Hungerreaktionen von Kriegsgefangenen. *Psyche* 1950;4:107–19.
104. Kas MJ, van Dijk G, Scheurink AJ, et al. Agouti-related protein prevents self-starvation. *Mol Psychiatry* 2003;8:235–40.
105. Hillebrand JJ, Kas MJ, Adan RA. Alpha-MSH enhances activity-based anorexia. *Peptides* 2005;26:1690–6.
106. Challet E, le Maho Y, Robin JP, et al. Involvement of corticosterone in the fasting-induced rise in protein utilization and locomotor activity. *Pharmacol Biochem Behav* 1995;50:405–12.
107. Lin WJ, Singer G, Papasava M. The role of adrenal corticosterone in schedule-induced wheel running. *Pharmacol Biochem Behav* 1988;30:101–6.
108. Wolkowitz OM. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. *Psychoneuroendocrinology* 1994;19:233–55.
109. Pechnik RN, Kariagina A, Hartvig E, et al. Developmental exposure to corticosterone: behavioral changes and differential effects on leukemia inhibitory factor (LIF) and corticotropin-releasing hormone (CRH) gene expression in the mouse. *Psychopharmacology (Berl)* 2006;185:76–83.
110. Klein DA, Mayer LE, Schebendach JE, et al. Physical activity and cortisol in anorexia nervosa. *Psychoneuroendocrinology* 2007;32:539–47.
111. Harvey J. Leptin regulation of neuronal excitability and cognitive function. *Curr Opin Pharmacol* 2007;7:643–7.
112. Kemps E, Tiggemann M, Wade T. Selective working memory deficits in anorexia nervosa. *Eur Eat Disord Rev* 2006;14:97–103.